SI3433232T1 - Nova kislinska dodatna sol 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoksi-1H-pirol- 3-IL)-N-metilmetanamina - Google Patents
Nova kislinska dodatna sol 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoksi-1H-pirol- 3-IL)-N-metilmetanaminaInfo
- Publication number
- SI3433232T1 SI3433232T1 SI201730396T SI201730396T SI3433232T1 SI 3433232 T1 SI3433232 T1 SI 3433232T1 SI 201730396 T SI201730396 T SI 201730396T SI 201730396 T SI201730396 T SI 201730396T SI 3433232 T1 SI3433232 T1 SI 3433232T1
- Authority
- SI
- Slovenia
- Prior art keywords
- methylmethanamine
- pyrrol
- difluorophenyl
- fluorophenyl
- sulfonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160036081 | 2016-03-25 | ||
| KR1020170018336A KR20170113040A (ko) | 2016-03-25 | 2017-02-09 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염 |
| PCT/KR2017/002913 WO2017164575A1 (en) | 2016-03-25 | 2017-03-17 | Novel acid addition salt of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n- methylmethanamine |
| EP17770545.6A EP3433232B1 (en) | 2016-03-25 | 2017-03-17 | Novel acid addition salt of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n- methylmethanamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3433232T1 true SI3433232T1 (sl) | 2020-10-30 |
Family
ID=60141235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201730396T SI3433232T1 (sl) | 2016-03-25 | 2017-03-17 | Nova kislinska dodatna sol 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoksi-1H-pirol- 3-IL)-N-metilmetanamina |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US10487053B2 (sl) |
| EP (1) | EP3433232B1 (sl) |
| JP (1) | JP6609065B2 (sl) |
| KR (2) | KR20170113040A (sl) |
| CN (1) | CN108602771B (sl) |
| AR (1) | AR107964A1 (sl) |
| AU (1) | AU2017238917B2 (sl) |
| BR (1) | BR112018069540A2 (sl) |
| CA (1) | CA3014753C (sl) |
| CL (1) | CL2018002415A1 (sl) |
| CO (1) | CO2018008834A2 (sl) |
| DO (2) | DOP2018000191A (sl) |
| ES (1) | ES2811478T3 (sl) |
| HK (1) | HK1254394A1 (sl) |
| HR (1) | HRP20201571T1 (sl) |
| HU (1) | HUE053741T2 (sl) |
| JO (1) | JOP20170071B1 (sl) |
| MA (1) | MA43832B1 (sl) |
| MX (1) | MX2018009220A (sl) |
| MY (1) | MY196355A (sl) |
| NZ (1) | NZ745267A (sl) |
| PE (1) | PE20190169A1 (sl) |
| PH (1) | PH12018501845A1 (sl) |
| PL (1) | PL3433232T3 (sl) |
| PT (1) | PT3433232T (sl) |
| RS (1) | RS60857B1 (sl) |
| SG (1) | SG11201806968RA (sl) |
| SI (1) | SI3433232T1 (sl) |
| TN (1) | TN2018000269A1 (sl) |
| TW (1) | TWI607753B (sl) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102081920B1 (ko) | 2016-03-25 | 2020-02-26 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형 |
| KR102233455B1 (ko) * | 2017-06-21 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| EP4079293A4 (en) * | 2019-12-18 | 2024-01-03 | Daewoong Pharmaceutical Co., Ltd. | LIQUID PHARMACEUTICAL COMPOSITION OF 1-(5-(2,4-DIFLUORPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANEAMINE |
| BR112022025613A2 (pt) * | 2020-06-17 | 2023-01-17 | Ildong Pharmaceutical Co Ltd | Novo inibidor de secreção de ácido e uso do mesmo |
| EP4245298A1 (en) * | 2020-12-18 | 2023-09-20 | Daewoong Pharmaceutical Co., Ltd. | Novel formulation for oral administration, comprising 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine |
| KR20230091056A (ko) * | 2021-12-15 | 2023-06-22 | 일동제약(주) | 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 |
| WO2023113474A1 (ko) * | 2021-12-15 | 2023-06-22 | 일동제약(주) | 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 |
| WO2023211843A1 (en) * | 2022-04-25 | 2023-11-02 | Daewoong Pharmaceutical Co., Ltd. | Potassium-competitive acid blockers for the treatment of pathological hypersecretory conditions |
| TW202411215A (zh) * | 2022-05-23 | 2024-03-16 | 南韓商日東製藥股份有限公司 | ６－甲氧基吡啶－３－基衍生物之製造方法 |
| TW202411216A (zh) * | 2022-05-23 | 2024-03-16 | 南韓商日東製藥股份有限公司 | ６－甲氧基吡啶－３－基衍生物之製造方法 |
| CN117820193A (zh) * | 2022-09-29 | 2024-04-05 | 安徽皓元药业有限公司 | 一种非苏拉赞盐酸盐晶型a及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2582777A1 (en) * | 2004-09-30 | 2006-04-06 | Takeda Pharmaceutical Company Limited | Proton pump inhibitors |
| ME00610B (me) | 2005-08-30 | 2011-12-20 | Takeda Pharmaceuticals Co | 1 –heterociklilsulfonil, 2 –aminometil, 5– (hetero–) aril supstituisan 1–h–pirol derivati kao inhibitori lučenja kiseline |
| JP5207964B2 (ja) * | 2006-03-31 | 2013-06-12 | 武田薬品工業株式会社 | 酸分泌抑制薬 |
| US20100113524A1 (en) * | 2006-09-19 | 2010-05-06 | Garst Michael E | Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety |
| US8933105B2 (en) * | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| KR20150084974A (ko) * | 2012-11-19 | 2015-07-22 | 장쑤 한서 파마슈티칼 캄파니 리미티드 | 피롤 설폰아미드 유도체, 이의 제조 방법, 및 이의 의학적 적용 |
| JP6343600B2 (ja) * | 2013-02-28 | 2018-06-13 | 武田薬品工業株式会社 | スルホニルクロライド化合物の製造法 |
| KR102084185B1 (ko) * | 2013-08-29 | 2020-03-04 | 주식회사 대웅제약 | 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법 |
| CN104447491B (zh) | 2014-11-19 | 2017-06-23 | 连云港恒运医药有限公司 | 含吡咯环质子泵抑制剂的半富马酸盐及其中间体和医药用途 |
| CN104447490B (zh) * | 2014-11-19 | 2017-06-06 | 连云港恒运医药有限公司 | 一种质子泵抑制剂的晶型、制备中间体及其合成方法和医药用途 |
| KR101613245B1 (ko) * | 2015-04-27 | 2016-04-18 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
-
2017
- 2017-02-09 KR KR1020170018336A patent/KR20170113040A/ko not_active Application Discontinuation
- 2017-03-17 RS RS20201178A patent/RS60857B1/sr unknown
- 2017-03-17 PE PE2018001575A patent/PE20190169A1/es unknown
- 2017-03-17 AU AU2017238917A patent/AU2017238917B2/en active Active
- 2017-03-17 SI SI201730396T patent/SI3433232T1/sl unknown
- 2017-03-17 HU HUE17770545A patent/HUE053741T2/hu unknown
- 2017-03-17 MA MA43832A patent/MA43832B1/fr unknown
- 2017-03-17 CA CA3014753A patent/CA3014753C/en active Active
- 2017-03-17 JP JP2018549922A patent/JP6609065B2/ja active Active
- 2017-03-17 BR BR112018069540A patent/BR112018069540A2/pt active IP Right Grant
- 2017-03-17 CN CN201780008658.9A patent/CN108602771B/zh active Active
- 2017-03-17 MY MYPI2018703343A patent/MY196355A/en unknown
- 2017-03-17 SG SG11201806968RA patent/SG11201806968RA/en unknown
- 2017-03-17 EP EP17770545.6A patent/EP3433232B1/en active Active
- 2017-03-17 ES ES17770545T patent/ES2811478T3/es active Active
- 2017-03-17 PL PL17770545T patent/PL3433232T3/pl unknown
- 2017-03-17 MX MX2018009220A patent/MX2018009220A/es unknown
- 2017-03-17 US US16/073,388 patent/US10487053B2/en active Active
- 2017-03-17 PT PT177705456T patent/PT3433232T/pt unknown
- 2017-03-17 NZ NZ745267A patent/NZ745267A/en unknown
- 2017-03-17 TN TNP/2018/000269A patent/TN2018000269A1/en unknown
- 2017-03-21 TW TW106109336A patent/TWI607753B/zh active
- 2017-03-22 JO JOP/2017/0071A patent/JOP20170071B1/ar active
- 2017-03-23 AR ARP170100727A patent/AR107964A1/es unknown
-
2018
- 2018-08-23 CL CL2018002415A patent/CL2018002415A1/es unknown
- 2018-08-24 CO CONC2018/0008834A patent/CO2018008834A2/es unknown
- 2018-08-30 PH PH12018501845A patent/PH12018501845A1/en unknown
- 2018-08-31 DO DO2018000191A patent/DOP2018000191A/es unknown
- 2018-10-19 HK HK18113471.1A patent/HK1254394A1/zh unknown
-
2020
- 2020-08-24 KR KR1020200106002A patent/KR102417830B1/ko active IP Right Grant
- 2020-10-04 HR HRP20201571TT patent/HRP20201571T1/hr unknown
-
2021
- 2021-01-06 DO DO2021000001A patent/DOP2021000001A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1254394A1 (zh) | 1-(5-(2，4-二氟苯基)-1-((3-氟苯基)磺酰基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺的新酸加成鹽 | |
| HK1254393A1 (zh) | 1-(5-(2，4-二氟苯基)-1-((3-氟苯基)磺酰基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺鹽新晶型 | |
| SG11202005698XA (en) | Cyclohexyl acid triazole azines as lpa antagonists | |
| EP3621624A4 (en) | CYCLIC DINUCLEOTIDIC COMPOUNDS AS STING AGONISTS | |
| SG11202005703TA (en) | Cyclohexyl acid triazole azoles as lpa antagonists | |
| EP3344644A4 (en) | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | |
| CU20170057A7 (es) | Derivados de feniltriazol sustituido con hidroxialquilo | |
| CL2016003145A1 (es) | Compuestos de [1,2,4]triazol sustituido | |
| IL247901A0 (en) | Additional salts of (s)-2-(1-(6-amino-5-cyanopyrimidine-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1 ,2,4]triazine-5-carbonitrile | |
| WO2015143188A8 (en) | 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation | |
| EP3727401A4 (en) | CYCLIC DINUCLEOTIDE COMPOUNDS USED AS STING AGONISTS | |
| MA45185A (fr) | Composé de sulfonamide ou son sel | |
| EP3140291A4 (en) | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease | |
| MX2019011789A (es) | 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion. | |
| EP3589623C0 (en) | PRODUCTION OF 2,5-FURANDIC ACID | |
| ZA201803510B (en) | Process for the production of 2,5-furandicarboxylic acid (fdca) | |
| MX2016014857A (es) | Compuestos de [1,2,4]triazol e imidazol sustituidos como fungicidas. | |
| EA201691999A1 (ru) | Новые сульфониламинобензамидные соединения | |
| IL283408A (en) | Pyrazoles as modulators of hemoglobin | |
| ZA201600021B (en) | 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator | |
| EP4079293A4 (en) | LIQUID PHARMACEUTICAL COMPOSITION OF 1-(5-(2,4-DIFLUORPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANEAMINE | |
| EP3383868A4 (en) | ARYL SULFONAMIDES AS BLT1 ANTAGONISTS | |
| WO2016138538A3 (en) | Therapeutic use of integrin-binding antibodies | |
| EP3728178A4 (en) | SYNTHESIS OF AZELIC ACID | |
| GR1008554B (el) | Φαρμακευτικο σκευασμα περιεχον εναν αντιμυκητιασικο παραγοντα τριaζολης και μεθοδος για την παρασκευη αυτου |